Market Cap 3.48B
Revenue (ttm) 75.13M
Net Income (ttm) -146.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -194.88%
Debt to Equity Ratio 0.00
Volume 4,951,100
Avg Vol 8,325,590
Day's Range N/A - N/A
Shares Out 306.61M
Stochastic %K 49%
Beta 1.20
Analysts Strong Sell
Price Target $16.12

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 W 4th Avenue, Vancouver, Canada
MagicRon_
MagicRon_ Sep. 1 at 4:30 PM
$ABCL LOL the state of you BullTards as if your pocket money is moving a 4 bill MC stock. Just deal with reality this is going back to $5. And get a job, dossers.
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 1 at 3:55 PM
$ABCL WE ABOUT to TAKE OFF and TACKLE $12’sssss! CONSOLIDATION DONE ✅ HUGE BUY’S COMING in!! A LOT is HAPPENING with ABCL and with ABCL 575 data coming this QUARTER coming from the CEO CARL. With SEVERAL MANAGEMENT BUYING OVER $2,000,000 MILLION dollars in shares in the OPEN MARKET at $11. 1 thing is FOR SURE WE GOING MUCH HIGHER and this is JUST the BEGINNING!!!! BOOM!!! BOOM 💥!! BUY NOW JOIN US for the RIDE!!! ABCL is the #FUTURE of MEDICINE 💊
2 · Reply
Buying_Low_Selling_High
Buying_Low_Selling_High Sep. 1 at 3:53 PM
$ABCL Bears are trying but its becoming harder and harder to keep it this low. Huge upwards momentum coming....
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 1 at 3:21 PM
$ABCL $ABCL GET IN NOW!!! BUY..BUY..! What a gift at these prices. $13’ss-15’ss this week. Do you all UNDERSTAND that the ABCL 575 is coming OUT this QUARTER!! CARL said 575 COMING this QUARTER!!! MANAGEMENT just bought over 2 MILLION of SHARES in the OPEN MARKET at $11!! ONLY FOR 1 REASON…they KNOW SOMETHING and we ABOUT to SKYROCKET in PRICE $$15-$20’ssss plus!!!
3 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 1 at 3:03 PM
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 1 at 2:58 PM
$ABCL DON’T let the SHORT’s STEAL or BORROW YOUR SHARES!!! It is done consolidating going to $13-15’ss this week. SHORTS don’t know what to do they are NERVOUS!! SHORT INTEREST @ 43MILLION!!!!
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 1 at 2:40 PM
$ABCL EXACTLY!!
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 1 at 2:31 PM
$ABCL $ABCL GET in NOW!! Don’t stay in the SIDELINES!! CONSOLIDATION is OVER we are moving to the NEXT LEG Up $$13-15’ssssss
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 1 at 2:22 PM
$ABCL VERY NICE BUY’s! $600,000 WORTH! Been CONSOLIDATING for a few day’s $12’sss COMING up. My CHART 📈 has given me the GREEN CANDLE!! It’s GO TIME $12’sss next!
0 · Reply
FGA
FGA Sep. 1 at 1:30 PM
$ABCL same BS different day! Double D's are always trying to make you sell! Patience pays in a GRAND way!
0 · Reply
Latest News on ABCL
AbCellera rises 17.0%

2026-08-25T16:06:05.000Z - 7 days ago

AbCellera rises 17.0%


AbCellera rises 10.7%

2026-08-25T14:06:36.000Z - 7 days ago

AbCellera rises 10.7%


AbCellera announces $200M common stock, warrants offering

2026-08-11T20:05:47.000Z - 20 days ago

AbCellera announces $200M common stock, warrants offering


AbCellera price target raised to $30 from $12 at Truist

2026-08-11T13:35:37.000Z - 21 days ago

AbCellera price target raised to $30 from $12 at Truist


AbCellera Biologics Slides: Corporate presentation

Aug 10, 2026, 8:00 AM EDT - 22 days ago

AbCellera Biologics Slides: Corporate presentation


AbCellera Biologics Transcript: Study result

Aug 10, 2026, 7:30 AM EDT - 22 days ago

AbCellera Biologics Transcript: Study result


AbCellera Biologics Press release: Study result

Aug 10, 2026, 7:30 AM EDT - 22 days ago

AbCellera Biologics Press release: Study result


AbCellera Biologics Slides: Study result

Aug 10, 2026, 7:30 AM EDT - 22 days ago

AbCellera Biologics Slides: Study result


AbCellera price target raised to $9 from $8 at Stifel

2026-08-06T12:20:50.000Z - 26 days ago

AbCellera price target raised to $9 from $8 at Stifel


AbCellera Biologics Earnings Call Transcript: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 26 days ago

AbCellera Biologics Earnings Call Transcript: Q2 2026


AbCellera Biologics Slides: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 26 days ago

AbCellera Biologics Slides: Q2 2026


AbCellera Biologics Earnings release: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 26 days ago

AbCellera Biologics Earnings release: Q2 2026


AbCellera Biologics Quarterly report: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 26 days ago

AbCellera Biologics Quarterly report: Q2 2026


AbCellera Reports Q2 2026 Business Results

Aug 5, 2026, 4:05 PM EDT - 26 days ago

AbCellera Reports Q2 2026 Business Results


AbCellera upgraded to Buy from Hold at Benchmark

2026-07-07T10:35:14.000Z - 2 months ago

AbCellera upgraded to Buy from Hold at Benchmark

JAZZ


AbCellera apponts Lynn Seely to board of directors

2026-07-06T13:15:29.000Z - 2 months ago

AbCellera apponts Lynn Seely to board of directors

LYEL


AbCellera Appoints Dr. Lynn Seely to its Board of Directors

Jul 6, 2026, 9:00 AM EDT - 2 months ago

AbCellera Appoints Dr. Lynn Seely to its Board of Directors


AbCellera Appoints Dr. Victor Sandor to its Board of Directors

Jun 5, 2026, 9:00 AM EDT - 3 months ago

AbCellera Appoints Dr. Victor Sandor to its Board of Directors


AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

AbCellera Biologics Earnings Call Transcript: Q1 2026


AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

AbCellera Biologics Earnings release: Q1 2026


AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

AbCellera Biologics Quarterly report: Q1 2026


AbCellera Biologics Slides: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

AbCellera Biologics Slides: Q1 2026


AbCellera Biologics Slides: Corporate presentation

May 1, 2026, 8:00 AM EDT - 4 months ago

AbCellera Biologics Slides: Corporate presentation


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025


AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Annual report: Q4 2025


AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings release: Q4 2025


AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Slides: Q4 2025


AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 6 months ago

AbCellera Reports Full Year 2025 Business Results


AbCellera Biologics Slides: Corporate presentation

Jan 14, 2026, 7:00 AM EST - 8 months ago

AbCellera Biologics Slides: Corporate presentation


AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

Nov 13, 2025, 8:00 AM EST - 10 months ago

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference


AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 10 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors


AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025


AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Quarterly report: Q3 2025


AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Earnings release: Q3 2025


AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Slides: Q3 2025


AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 10 months ago

AbCellera Reports Q3 2025 Business Results


AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2025


AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q2 2025


AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q2 2025


AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q2 2025


AbCellera Biologics Slides: Corporate Presentation

Aug 1, 2025, 7:00 AM EDT - 1 year ago

AbCellera Biologics Slides: Corporate Presentation


AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025


AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025


AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025


AbCellera Biologics Slides: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025


AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024


AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024


AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024


AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024


AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results


AbCellera Biologics Slides: FY 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025


AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024


AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024


AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024


AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024


AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results


MagicRon_
MagicRon_ Sep. 1 at 4:30 PM
$ABCL LOL the state of you BullTards as if your pocket money is moving a 4 bill MC stock. Just deal with reality this is going back to $5. And get a job, dossers.
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 1 at 3:55 PM
$ABCL WE ABOUT to TAKE OFF and TACKLE $12’sssss! CONSOLIDATION DONE ✅ HUGE BUY’S COMING in!! A LOT is HAPPENING with ABCL and with ABCL 575 data coming this QUARTER coming from the CEO CARL. With SEVERAL MANAGEMENT BUYING OVER $2,000,000 MILLION dollars in shares in the OPEN MARKET at $11. 1 thing is FOR SURE WE GOING MUCH HIGHER and this is JUST the BEGINNING!!!! BOOM!!! BOOM 💥!! BUY NOW JOIN US for the RIDE!!! ABCL is the #FUTURE of MEDICINE 💊
2 · Reply
Buying_Low_Selling_High
Buying_Low_Selling_High Sep. 1 at 3:53 PM
$ABCL Bears are trying but its becoming harder and harder to keep it this low. Huge upwards momentum coming....
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 1 at 3:21 PM
$ABCL $ABCL GET IN NOW!!! BUY..BUY..! What a gift at these prices. $13’ss-15’ss this week. Do you all UNDERSTAND that the ABCL 575 is coming OUT this QUARTER!! CARL said 575 COMING this QUARTER!!! MANAGEMENT just bought over 2 MILLION of SHARES in the OPEN MARKET at $11!! ONLY FOR 1 REASON…they KNOW SOMETHING and we ABOUT to SKYROCKET in PRICE $$15-$20’ssss plus!!!
3 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 1 at 3:03 PM
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 1 at 2:58 PM
$ABCL DON’T let the SHORT’s STEAL or BORROW YOUR SHARES!!! It is done consolidating going to $13-15’ss this week. SHORTS don’t know what to do they are NERVOUS!! SHORT INTEREST @ 43MILLION!!!!
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 1 at 2:40 PM
$ABCL EXACTLY!!
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 1 at 2:31 PM
$ABCL $ABCL GET in NOW!! Don’t stay in the SIDELINES!! CONSOLIDATION is OVER we are moving to the NEXT LEG Up $$13-15’ssssss
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 1 at 2:22 PM
$ABCL VERY NICE BUY’s! $600,000 WORTH! Been CONSOLIDATING for a few day’s $12’sss COMING up. My CHART 📈 has given me the GREEN CANDLE!! It’s GO TIME $12’sss next!
0 · Reply
FGA
FGA Sep. 1 at 1:30 PM
$ABCL same BS different day! Double D's are always trying to make you sell! Patience pays in a GRAND way!
0 · Reply
Rastafari
Rastafari Sep. 1 at 12:57 PM
$ABCL The coil is tight and loaded. The stock is going to finish in the green today. Don’t get shaken out by the pre-market drop—stay focused and hold your conviction! Remember the movement yesterday? It was a .70c swing!
1 · Reply
MagicRon_
MagicRon_ Sep. 1 at 12:17 PM
$ABCL Good time for a short report - Ive send the lead to Hindenburg, Culpe and a few others
2 · Reply
tiddyy
tiddyy Sep. 1 at 5:28 AM
$ABCL Alright third times the charm guys, $13 please. Today.
0 · Reply
Rastafari
Rastafari Sep. 1 at 1:53 AM
$ABCL expect ABCL to regain $12 tomorrow. I am not Nostradamus, but the momentum is there.
0 · Reply
PLTRLONGDONG
PLTRLONGDONG Sep. 1 at 1:17 AM
$ABCL this will be $25 end of year
0 · Reply
Buying_Low_Selling_High
Buying_Low_Selling_High Sep. 1 at 12:44 AM
$ABCL What a dissapointing day for bears. great reversal and lesson for shorts. dips are bought by smart money.
0 · Reply
CapitalMonk
CapitalMonk Aug. 31 at 8:38 PM
$ABCL Price: $11.48 (-7.42%) Trend: Bullish Market Bias (7D): Bullish Bias 📈 Expected Range: ±17.51% RSI: 63.7 | Momentum: Strong Momentum Volume: -52.7% vs avg Volatility: 9.42% Support: $5.57 | Resistance: $12.58 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai
0 · Reply
Rastafari
Rastafari Aug. 31 at 6:30 PM
$ABCL summary My ranking for ABCL’s next big partnership Regeneron > AstraZeneca > Lilly > BMS > Roche And I’d add one important wildcard: AbbVie. AbbVie is already an AbCellera partner, and the relationship was expanded in 2025 specifically to include T-cell engagers for oncology. It also continues to spend aggressively on external bispecific technology—its 2026 RemeGen deal included a $650M upfront payment and up to $4.95B in milestones. That makes AbbVie potentially the easiest company to envision doing another, larger AbCellera transaction.
0 · Reply
Rastafari
Rastafari Aug. 31 at 6:29 PM
$ABCL part 5 5. Roche / Genentech Roche is a slightly different proposition. It already possesses enormous internal antibody and bispecific capabilities, so it doesn’t have the same obvious need for AbCellera’s technology. But Roche also has one of the world’s largest oncology businesses, and the commercial success of bispecifics has made the modality increasingly attractive across the industry. A highly differentiated AbCellera TCE—particularly one addressing a difficult solid tumor or autoimmune target—could therefore be interesting. Probability: ~15–20%.
0 · Reply
Rastafari
Rastafari Aug. 31 at 6:28 PM
$ABCL part 4 4. Bristol Myers Squibb BMS is a natural candidate because of its enormous immuno-oncology business. The company has been aggressively acquiring external immunology/oncology technologies, including its $1.5 billion acquisition of Orbital Therapeutics. BMS’s recent termination of its Cellares manufacturing agreement doesn’t change my view of its appetite for external innovation; that was a manufacturing-platform issue rather than evidence that BMS is backing away from immunotherapy. Probability: ~20%.
0 · Reply
Rastafari
Rastafari Aug. 31 at 6:28 PM
$ABCL part 3 3. Eli Lilly and Company Lilly is becoming increasingly interesting. Just today, Lilly announced an acquisition of Merida Biosciences for up to $2.875 billion, specifically to expand into autoimmune and allergic disease. That is important because Vertex’s AbCellera deal is focused on autoimmune disease. Lilly also has the financial firepower to make a substantial platform investment. Its recent acquisition activity demonstrates that it is willing to spend heavily to expand its pipeline. And there is another strategic angle: Lilly was an early AbCellera investor, so there is already familiarity between the organizations. Probability: ~20–25%
0 · Reply
Rastafari
Rastafari Aug. 31 at 6:25 PM
$ABCL part 2 1. Regeneron Pharmaceuticals — my #1 This is the company I’d watch most closely. Regeneron already has substantial expertise in bispecific antibodies through its Veloci-Bi platform. In June 2026, Regeneron expanded its collaboration with CytomX around conditional bispecific cancer therapies; that expansion gives Regeneron options on additional programs and carries potential milestones of roughly $4 billion. That’s almost exactly the type of commercial behavior that makes an AbCellera deal conceivable. Why AbCellera fits: AbCellera could provide Regeneron with differentiated TCE targets, novel CD3 arms, costimulatory arms and multispecific formats without Regeneron having to build every capability internally. Probability I’d assign: ~30% of a meaningful AbCellera collaboration within the next 12–24 months.
0 · Reply